Naloxone Inhibition of lipopolysaccharide-induced activation of retinal microglia is partly mediated via the p38 mitogen activated protein kinase signalling pathway

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1438-1448

  Xu, Y F ^a   Fu, L L ^b   Jiang, Ch ^a   Qin, Y W ^a   Ni, Y Q ^a   Fan, J W ^a  

^a FUDAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Naloxone; Neuroprotection; P38 mapk; Retinal microglia

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; NALOXONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MICROGLIA; NONHUMAN; RAT; RETINA CELL; SIGNAL TRANSDUCTION; SUPERNATANT; WESTERN BLOTTING;

EID: 84867569777     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000422     Document Type: Article

References (59)

1. Garden GA, La Spada AR: Intercellular (mis)communication in neurodegenerative disease. Neuron 2012; 73: 886 - 901.
2. Wilms H, Zecca L, Rosenstiel P, et al: Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 2007; 13: 1925 - 1928.
3. Xu L, Wang Y, Li Y, et al: Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006; 113: 1134el - 1134ell.
4. Seddon JM, Chen CA: Epidemiology of agerelated macular degeneration. In: Retina, 4th edn (Ryan SJ, ed). Philadelphia: Elsevier, 2006; pp 1017 - 1028.
5. Frank RN: Etiologic mechanisms in diabetic retinopathy. In: Retina, 4th edn (Ryan SJ, ed). Philadelphia: Elsevier, 2006; pp 1241 - 1270.
6. Weleber RG, Gregory-Evans K: Retinitis pigmentosa and allied disorders. In: Retina, 4th edn (Ryan SJ, ed). Philadelphia: Elsevier, 2006; pp 395 - 497.
7. Rivest S: Regulation of innate immune responses in the brain. Nat Rev Immunol 2009; 9: 429 - 439.
8. Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77 - 98.
9. Ding X, Patel M, Chan CC: Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28: 1 18.
10. Combadière C, Feumi C, Raoul W, et al: CX3CRl-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. Clin Invest 2007; 117: 2920 - 2928.
11. Lieth E, Barber AJ, Xu B, et al: Glial reactivity and impaired glutamate metabolism in shortterm experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998; 47: 815 - 820.
12. Rogove AD, Tsirka SE: Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr Biol 1998; 8: 19-25. (Pubitemid 28056250)
13. Bronstein DM, Perez-Otano I, Sun V, et al: Gliadependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 1995; 704: 112-116.
14. Matsuoka Y, Kitamura Y, Takahashi H, et al: Interferon-y plus lipopolysaccharide induction of delayed neuronal apoptosis in rat hippocampus. Neurochem Int 1999; 34: 91 - 99.
15. Minghetti L, Levi G: Microglia as effector cellsin brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998; 54: 99 - 125.
16. Das KP, McMillian MK, Bing G, et al: Modulatory effects of [Met5]-enkephalin on interleukin-lβ secretion from microglia in mixed brain cell cultures. J Neuroimmunol 1995; 62: 9-17. (Pubitemid 3000888)
17. Krady JK, Basu A, Allen CM, et al: Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005; 54: 1559 - 1565.
18. Zeng XX, Ng YK, Ling EA: Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 2000; 17: 463 - 471.
19. Liu B, Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. Pharmacol Exp Ther 2003; 304: 1 - 7.
20. Schuetz E, Thanos S: Neuro-glial interactions in the adult rat retina after reaxotomy of ganglion cells: examination of neuron survival and phagocytic microglia using fluorescent tracers. Brain Res Bull 2004; 62: 391 - 396.
21. Thanos S, Mey J, Wild M: Treatment of the adult retina with microglia-suppressing factors retards axotomy-induced neuronal degradation and enhances axonal regeneration in vivo and in vitro. J Neurosci 1993; 13: 455 - 466.
22. Jeohn GH, Cooper CL, Jang KJ, et al: GÖ6976 inhibits LPS-induced microglial TNF-a release by suppressing p38 MAP kinase activation. Neuroscience 2002; 114: 689 - 697.
23. Knapp RJ, Malatynska E, Collins N, et al: Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995; 9: 516 - 525.
24. Ni YQ Xu GZ, Hu WZ, et al: Neuroprotective effects of naloxone against light-induced photoreceptor degeneration through inhibiting retinal microglial activation. Invest Ophthalmol Vis Sci 2008; 49: 2589 - 2598.
25. Gwak MS, Li L, Zuo Z: Morphine preconditioning reduces lipopolysaccharide and interferon-y-induced mouse microglial cell injury via 81 opioid receptor activation. Neuroscience 2010; 167: 256 - 260.
26. Zhang P, Lokuta KM, Turner DE, et al: Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia. J Neurochem 2010; 112: 434 - 443.
27. Liu B, Du L, Hong JS: Naloxone protects rat dopaminergic neurons against inflammatorydamage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000; 293: 607 - 617.
28. Kong LY, McMillian MK, Hudson PM, et al: Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. J Pharmacol Exp Ther 1997; 280: 61 66.
29. Liu B, Du L, Kong LY, et al: Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia cocultures. Neuroscience 2000; 97: 749 - 756.
30. Widmann C, Gibson S, Jarpe MB, et al: Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999; 79: 143 - 180.
31. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912. (Pubitemid 35425238)
32. Shi Y, Gaestel M: In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biol Chem 2002; 383: 1519-1536. (Pubitemid 35282972)
33. Ji RR, Suter MR: p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 2007; 3: 33.
34. Tsai RY, Tai YH, Tzeng JI, et al: Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience 2009; 159: 1244 - 1256.
35. The Association for Research in Vision and Ophthalmology (ARVO): Statement for the Use of Animals in Ophthalmic and Visual Research. Rockville: ARVO (available at: http://www.arvo.org/Policies/Statement-for-the- Use-of-Animals-in-Ophthalmic-and-Visual- Research/).
36. Kumar S, Jiang MS, Adams JL, et al: Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 1999; 263: 825 - 831.
37. Lawson LJ, Perry VH, Dri P, et al: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39: 151 - 170.
38. Caprioli J: Neuroprotection of the optic nerve in glaucoma. Acta Ophthalmol Scand 1997; 75: 364 -367.
39. Giulian D, Haverkamp LJ, Li J, et al: Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 1995; 27: 119 - 137.
40. Cao JJ, Li KS, Shen YQ: Activated immune cells in Parkinson's disease. Neuroimmune Pharmacol 2011; 6: 323 - 329.
41. Shen D, Cao X, Zhao L, et al: Naloxoneameliorates retinal lesions in Ccl2/Cx3crl double-deficient mice via modulation of microglia. Invest Ophthalmol Vis Sci 2011; 52: 2897 - 2904.
42. Gupta N, Brown KE, Milam AH: Activated microglia in human retinitis pigmentosa, lateonset retinal degeneration, and age-related macular degeneration. Exp Eye Res 2003; 76: 463-471. (Pubitemid 36299058)
43. Streit WJ, Graeber MB, Kreutzberg GW: Functional plasticity of microglia: a review. Glia 1988; 1: 301 - 307.
44. Wen YR, Tan PH, Cheng JK, et al: Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. / Formos Med Assoc 2011; 110: 487 - 494.
45. Popovich PG, Wei P, Stokes BT: Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997; 377: 443 - 464.
46. Boje KM, Arora PK: Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 1992; 587: 250 256.
47. Chao CC, Hu S, Molitor TW, et al: Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992; 149: 2736-2741.
48. Dawson VL, Dawson TM, Uhl GR, et al: Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci U S A 1993; 90: 3256 - 3259.
49. Gao HM, Hong JS, Zhang W, et al: Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002; 22: 782 - 790.
50. Qin L, Liu Y, Cooper C, et al: Microglia enhance β-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002; 83: 973 - 983.
51. Qin L, Block ML, Liu Y, et al: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005; 19: 550 - 557.
52. Du Y, Tang J, Li G, et al: Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci 2010; 51: 2158 - 2164.
53. Kreutzberg GW, Graeber MB, Streit WJ: Neuronglial relationship during regeneration of motorneurons. Metab Brain Dis 1989; 4: 81 - 85.
54. Cuenda A, Rouse J, Doza YN, et al: SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995; 364: 229 - 233.
55. Hirai S, Katoh M, Terada M, et al: MST/MLK2, a member of the mixed lineage kinase family, directly phosphorylates and activates SEKl, an activator of c-Jun N-terminal kinase/stressactivated protein kinase. J Biol Chem 1997; 272: 15167-15173.
56. Barber AJ, Lieth E, Khin SA, et al: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783 - 791.
57. Bien A, Seidenbecher CI, Böckers TM, et al: Apoptotic versus necrotic characteristics of retinal ganglion cell death after partial opticnerve injury. J Neurotrauma 1999; 16: 153 - 163.
58. Graeber MB, Li W, Rodriguez ML: Role of microglia in CNS inflammation. FEBS Lett 2011; 585: 3798 - 3805.
59. van Dorp EL, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf 2007; 6: 125 - 132.